

1. *Requirement for emergent coronary artery bypass surgery following percutaneous coronary intervention in the stent era*
Roy, P., et al.
Am J Cardiol, 2009. **103**(7): p. 950-3.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19327421

2. *Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D)*
Schwartz, L., et al.
Am J Cardiol, 2009. **103**(5): p. 632-8.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19231325

3. *Percutaneous versus surgical revascularization for multivessel coronary artery disease: a single center 10 year follow-up of SOS trial patients*
Buszman, P., et al.
Catheter Cardiovasc Interv, 2009. **74**(3): p. 420-6.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19360866

4. *PCI versus CABG for multivessel coronary disease in diabetics*
Tarantini, G., et al.
Catheter Cardiovasc Interv, 2009. **73**(1): p. 50-8.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19089938

5. *The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction*
Chaitman, B.R., et al.
Circulation, 2009. **120**(25): p. 2529-40.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19920001

6. *Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial*
Hlatky, M.A., et al.
Circulation, 2009. **120**(25): p. 2550-8.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19920002

7. *Comparison of drug-eluting stents and coronary artery bypass surgery for the treatment of multivessel coronary disease: three-year follow-up results from a single institution*

Li, Y., et al.

Circulation, 2009. **119**(15): p. 2040-50.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19349321

8. *Improving long-term outcomes following coronary artery bypass graft or percutaneous coronary revascularisation: results from a large, population-based cohort with first intervention 1995-2004*

Blackledge, H.M. and I.B. Squire

Heart, 2009. **95**(4): p. 304-11.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19001000

9. *Sirolimus-eluting stents, bare metal stents or coronary artery bypass grafting for patients with multivessel disease including involvement of the proximal left anterior descending artery: analysis of the Arterial Revascularization Therapies study part 2 (ARTS-II)*

Kukreja, N., et al.

Heart, 2009. **95**(13): p. 1061-6.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19304671

10. *Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room*

Zhao, D.X., et al.

J Am Coll Cardiol, 2009. **53**(3): p. 232-41.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19147039

11. *Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials*

Hlatky, M.A., et al.

Lancet, 2009. **373**(9670): p. 1190-7.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19303634

12. *A randomized trial of therapies for type 2 diabetes and coronary artery disease*

Frye, R.L., et al.

N Engl J Med, 2009. **360**(24): p. 2503-15.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19502645

13. *CABG vs. stenting--clinical implications of the SYNTAX trial*

Lee, T.H., L.D. Hillis, and E.G. Nabel

N Engl J Med, 2009. **360**(8): p. e10.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19228613

14. *Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease*

Serruys, P.W., et al.

N Engl J Med, 2009. **360**(10): p. 961-72.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19228612

15. *Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention*

Welsh, R.C., et al.

JACC Cardiovasc Interv, 2010. **3**(3): p. 343-51.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20298996

16. *Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial*

Kapur, A., et al.

J Am Coll Cardiol, 2010. **55**(5): p. 432-40.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20117456